



Corporate Overview
Annual General Meeting
11 March 2009

David Christie, President and CEO

Agenda

- F08 Achievements
- F09 Q1 Financial Results
- Strategic Priorities F09
- Investment Summary


Introduction

- Exchange/Symbol: 'PYT': TSX.V
- Shares Outstanding (basic): 10.5 million
- 52 week price range: \$0.69 - \$0.22
- Fiscal Year End: September 30
- Fiscal 2008 Revenue: \$6.5 million
- Research Coverage: Canaccord & Northern Sec.


*2008 Medical Device Company of the Year
Award: LifeSciences BC*

Growth Trajectory

Revenue (\$000)
FY2002 - FY 2008



Before-tax Operating Income (in '000)



F08 Revenue, GM & Income

- Revenue of \$6.55 million
 - 36% increase
- \$4.6 million Gross Margin or 70%
- \$1.33 million EBITDA
 - 20% of gross revenue
- \$859 thousand before-tax income
 - 13% of gross revenue
- \$310 thousand net income after tax

Fiscal 08 Key Accomplishments

- Expanded **FAST1** indications (>12 years)
- Launched improved **FAST1** (w/o remover)
- Sustained revenue growth:
 - 36% increase to \$6.5 million
 - 8th consecutive quarter of profitability
- Four-fold increase in product portfolio through initial asset acquisition
- Expanded international distribution network
- Enhanced Board, Management and Sales Team
- Awarded Medical Device Company of the Year

Asset Acquisition (June/08)

- Complimentary trauma products purchased from BCI
 - ***T-POD***® & ***MAT***®
 - Paid \$1.6 million cash
 - ***CRIC***™
 - FDA pending
 - \$750K(\$US) DOD grant to develop
 - Will pay \$780K(\$Cdn) in three installments

T-POD, MAT & CRIC


- All synergistic to our core product
 - Compliment ***FAST1*** and ABCs of resuscitation
- Same markets, same distributors, same call points, same people
- Adds significant revenues at comparable gross margins
- Very few direct costs (one sales person)
- Immediately accretive to earnings

Fiscal Q1/09 Results (Dec 31/08)

Revenue & Income

- \$1.6 million revenue
 - 25% growth over Q1/08
- \$1.2 million Gross Margin or 71%
- \$1.1 million operating expenses
- \$100 thousand cash flow from operations
- \$46 thousand net loss

25% Revenue Growth (Q1 yr/yr)



F09/Q1 Balance Sheet Dec. 31/08

- Current Assets: \$2 million
- Current Liabilities: \$2.2 million
 - including \$780 thousand accrual for future milestone payments on BCI
- Unutilized LOC: \$960,000
- Current cash balance: \$160K

Strategic Priorities Fiscal 2009

- **CRIC** launch: pending FDA clearance
- Secure hospital distributor
- **FASTx** launch
- Properly capitalize Pyng
- Expand US sales force

Product Launches

- 2 new products in the pipeline
 - Very well received in pre-selling
- CRIC FDA
 - Supervisory Review process: spring
 - No payments required until cleared
 - Expenditures reimbursed thru BAA grant
- CRIC CE Mark in-process
- FASTx
 - Spring submission planned
 - FAST1 is written in to DoD SOPs

Interim guidance F09 year-end

- \$6.5 million in revenue
- 25% operating expense reduction in second half over first half
- Continued profitability @ 12.8% EBITDA \$830 thousand

Financing supports growth

- To support milestone payments and US sales expansion
- Alternatively, milestones may be vendor or bank financed, and sales expansion deferred

Use of Funds

- New sales and marketing operating expenditures in the US
- Capital expenditures
 - BCI milestones pending CRIC FDA
- Exchange contingency

Investment Highlights

- Enhanced Board, Management & Sales team with aggressive growth strategy
- Market leading product portfolio
 - strong IP: 29 patents/patents pending
- Strong financial performance
 - 2.2 fold revenue growth in 2 years
 - 4 fold EBITDA growth in 2 years
 - 2.2 fold asset growth in 2 years

Investment Highlights

- Top-tier international distributor network (>180,000 devices sold)
- Multiple large market opportunities – US & ROW
- Credible third-party validation
- 2009 Milestones (commercial launch of ***FASTx*** and ***CRIC***)



For More Information

Pyng Medical Corp

www.pyng.com

TSX-V:PYT

David Christie

President and Chief Executive Officer

dchristie@pyng.com

1-800-349-7964

Thank you for your interest in Pyng Medical